Clone:
REA284
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC, ICC, MC
Alternative names:
KIR2DL1, KIR-K64, KIR221, NKAT, NKAT-1, p58.1

Extended validation for CD158a (KIR2DL1) Antibody, anti-human, REAfinity™

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REA284
HP-3E4++
HP-MA4+
Cells were incubated with an excess of purified unconjugated CD158a (KIR2DL1) (REA284) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for CD158a (KIR2DL1). Human peripheral blood mononuclear cells (PBMCs) were stained with CD158a (KIR2DL1) antibodies and with a suitable counterstaining. As a control, CD158a (KIR2DL1) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD158a (KIR2DL1). Human peripheral blood mononuclear cells (PBMCs) were stained with CD158a (KIR2DL1) antibodies and with a suitable counterstaining. As a control, CD158a (KIR2DL1) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD158a (KIR2DL1). Human peripheral blood mononuclear cells (PBMCs) were stained with CD158a (KIR2DL1) antibodies and with a suitable counterstaining. As a control, CD158a (KIR2DL1) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD158a (KIR2DL1). Human peripheral blood mononuclear cells (PBMCs) were stained with CD158a (KIR2DL1) antibodies and with a suitable counterstaining. As a control, CD158a (KIR2DL1) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD158a (KIR2DL1). Human peripheral blood mononuclear cells (PBMCs) were stained with CD158a (KIR2DL1) antibodies and with a suitable counterstaining. As a control, CD158a (KIR2DL1) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using CD158a (KIR2DL1) (REA284). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD158a (KIR2DL1) (REA284). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using CD158a (KIR2DL1) (REA284). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD158a (KIR2DL1) Antibody, anti-human, REAfinity™

Overview

Clone REA284 recognizes human CD158a (KIR2DL1), but not KIR2DL2, 2DL3, 2DL4, 2DL5, 2DS1, 2DS2, 2DS4, 3DL1, 3DL2, or 3DS1. CD158a is 58 kDa protein, also known as KIR2DL1. CD158a is a member of the family of killer cell immunoglobulin-like receptors (KIRs) comprising transmembrane glycoproteins expressed on NK cells and a subset of T cells. Many groups of KIRs exist including KIR3DL1-3, KIR3DS1, KIR2DL1-5, and KIR2DS1-5. The isoforms have either a short (S) or long (L) cytoplasmic domain which transduce either an activating or inhibitory signal, respectively. The ligands of CD158a (KIR2DL1) are HLA-C molecules with Asn77 and Lys80, but not Ser77 and Asn80.
Additional information: Clone REA284 displays negligible binding to Fc receptors.

Alternative names

KIR2DL1, KIR-K64, KIR221, NKAT, NKAT-1, p58.1

Detailed product information

Technical specifications

CloneREA284
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hostcell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman
AntigenCD158a (KIR2DL1)
Alternative names of antigenKIR2DL1, KIR-K64, KIR221, NKAT, NKAT-1, p58.1
Molecular mass of antigen [kDa]36
Distribution of antigenNK cells, T cells
Entrez Gene ID3802
RRIDAB_2733619, AB_2751524, AB_2751487, AB_2752154, AB_2752103, AB_2752152, AB_2752101, AB_2752155, AB_2752104, AB_2752153, AB_2752102, AB_2801860, AB_2655327, AB_2655328, AB_2733618

Resources for CD158a (KIR2DL1) Antibody, anti-human, REAfinity™

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD158a (KIR2DL1) Antibody, anti-human, REAfinity™

Publications

  1. Valés-Gómez, M. et al. (1998) Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors. Immunity 9(3): 337-333
  2. Wagtmann, N. et al. (1995) Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. Immunity 2(5): 439-449
  3. Fan, Q. R. et al. (2001) Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex. Nat. Immunol. 2(5): 452-460
  4. Colonna, M. et al. (1995) Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 268(5209): 405-408
  5. Jackson, E. et al. (2017) HIV exposed seronegative (HESN) compared to HIV infected individuals have higher frequencies of telomeric killer immunoglobulin-like receptor (KIR) B motifs; contribution of KIR B motif encoded genes to NK cell responsiveness. PLoS One 12(9): e0185160
  6. Chapel, A. et al. (2017) Peptide-specific engagement of the activating NK cell receptor KIR2DS1. Sci Rep 7(1): 2414
  7. Lu, W. et al. (2016)
    Suppression of HIV replication by CD8
    +
    regulatory T-cells in elite controllers.
    Front Immunol 7: 134

Related products for
CD158a (KIR2DL1) Antibody, anti-human, REAfinity™

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?